文献速递神经免疫

持续免疫治疗与活动性继发进展型多发性硬化残疾结局的关联

Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2020-01-01

基于MSBase国际登记的前瞻性观察队列,纳入1621例符合Lorscheider定义的继发进展型多发性硬化(SPMS)患者。SPMS期复发率升高与依赖轮椅风险增加相关(HR 1.87,95%CI 1.17-3.00,P=.009);在SPMS期有叠加复发的患者中,更多接受疾病修饰治疗与残疾进展减慢及轮椅依赖风险降低相关。

要点

  • SPMS期叠加复发与残疾进展加快及轮椅依赖风险升高相关
  • SPMS期有复发者中更多接受疾病修饰治疗与残疾结局改善相关
  • 早期复发缓解期的治疗与复发未显示与SPMS期残疾累积相关

核心结论

  • SPMS发病后的残疾进展速度与早期病程及治疗决策无关
  • SPMS期复发是可干预的治疗靶点,炎症活动仍是SPMS可修饰的组成部分

研究设计与样本

  • 观察性队列研究,数据来自MSBase国际登记,前瞻性收集1995年1月1日至2018年2月1日患者数据

主要发现

  • 纳入的1621例中1103例(68.0%)为女性,MS发病平均(SD)年龄33.9(10.6)岁
  • 661例(40.8%)在SPMS期出现叠加复发
  • SPMS期复发率越高,依赖轮椅风险越高(HR 1.87;95%CI 1.17-3.00;P=.009)
  • SPMS期有叠加复发的患者中,更多接受疾病修饰治疗与残疾进展速率降低及轮椅依赖风险降低显著相关

临床怎么用

  • 对SPMS期仍有复发的患者,可考虑持续疾病修饰治疗以减缓残疾进展
  • SPMS期复发应作为可干预的治疗目标加以评估和管理

局限性

  • 为观察性队列研究,治疗与结局的关联可能受适应证等混杂因素影响
  • 仅纳入随访充分者,可能存在选择偏倚

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It is unclear whether relapses and disease-modifying therapies are associated with the rate of disability accumulation in patients with secondary progressive multiple sclerosis (SPMS). OBJECTIVE: To examine the association of relapses with the rate of disability accumulation in patients with SPMS and to assess whether treatment before or during the secondary progressive phase can slow the progression of disability accumulation. DESIGN, SETTING, AND PARTICIPANTS: In this observational cohort study, patient data were prospectively collected from the MSBase international registry between January 1, 1995, and February 1, 2018. Among 53 680 patients in the MSBase registry, 4997 patients with SPMS (using the Lorscheider definition) were identified. Of those, 1621 patients were eligible for study inclusion based on sufficient follow-up before and after the onset of SPMS. Data were analyzed from November 15, 2017, to January 13, 2020. EXPOSURES: The association between disability accumulation and several clinical and demographic variables, including relapses and exposure to immunotherapy, was evaluated. MAIN OUTCOMES AND MEASURES: Two outcomes were analyzed as measures of disability accumulation during SPMS: the rate of disability accumulation during the secondary progressive phase (change relative to the reference population of patients with MS and absolute change) and the risk of becoming wheelchair dependent. A third outcome, the cumulative risk of experiencing confirmed disability progression events, was used for a secondary analysis. Outcomes were evaluated using multivariable mixed models (ie, linear and Cox models). RESULTS: Of 1621 patients eligible for inclusion, 1103 patients (68.0%) were female, with a mean (SD) age at MS onset of 33.9 (10.6) years. A total of 661 patients (40.8%) experienced superimposed relapses during SPMS. Therapy receipt and relapses during early relapsing-remitting MS were not associated with disability accumulation during the secondary progressive phase. Higher relapse rates during the secondary progressive disease stage were associated with an increased risk of becoming wheelchair dependent (hazard ratio [HR], 1.87; 95% CI, 1.17-3.00; P = .009). Among patients who experienced superimposed relapses during SPMS, greater receipt of disease-modifying therapies was significantly associated with a reduced rate of disability progression and a lower risk of becoming wheelchair dependent. CONCLUSIONS AND RELEVANCE: In this study, the rate of disability progression after the onset of SPMS was not associated with the early disease course and treatment decisions. Relapses during SPMS were associated with accelerated disability progression and represent an accessible treatment target. Disease-modifying therapy was associated with improvements in disability outcomes among patients with active relapses during SPMS. The study's results suggest that inflammatory disease activity remains a substantial yet modifiable component of SPMS.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Lizak N, Malpas CB, Sharmin S, et al. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. JAMA Neurol. 2020. PMID: 32716480. doi:10.1001/jamaneurol.2020.2453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。